Updates are available Correction dated 2024-08-22
Click to view Correction: https://doi.org/10.1038/s41467-024-51184-1
-
Authors
Forrest, Suzanne J. https://orcid.org/0000-0002-9797-7947
Gupta, Hersh
Ward, Abigail
Li, Yvonne Y. https://orcid.org/0000-0002-1741-1995
Doan, Duong
Al-Ibraheemi, Alyaa
Alexandrescu, Sanda
Bandopadhayay, Pratiti https://orcid.org/0000-0002-4175-4760
Shusterman, Suzanne
Mullen, Elizabeth A. https://orcid.org/0000-0002-6704-0002
Collins, Natalie B. https://orcid.org/0000-0003-2980-9244
Chi, Susan N.
Wright, Karen D.
Kumari, Priti
Mazor, Tali https://orcid.org/0000-0002-0138-9615
Ligon, Keith L. https://orcid.org/0000-0002-7733-600X
Shivdasani, Priyanka
Manam, Monica
MacConaill, Laura E.
Ceca, Evelina
Benich, Sidney N.
London, Wendy B. https://orcid.org/0000-0003-3571-6538
Schilsky, Richard L. https://orcid.org/0000-0003-4474-4303
Bruinooge, Suanna S. https://orcid.org/0000-0002-9936-2719
Guidry Auvil, Jaime M.
Cerami, Ethan
Rollins, Barrett J.
Meyerson, Matthew L. https://orcid.org/0000-0002-9133-8108
Lindeman, Neal I.
Johnson, Bruce E.
Cherniack, Andrew D. https://orcid.org/0000-0003-0470-0111
Church, Alanna J. https://orcid.org/0000-0002-4835-5770
Janeway, Katherine A. https://orcid.org/0000-0001-6000-3594
- License Information
-
More Information
Article History
Received: 28 October 2023
Accepted: 18 June 2024
First Online: 11 July 2024
Change Date: 22 August 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-024-51184-1
Competing interests
: The following represents disclosure information provided by the authors of this manuscript. Relationships may not relate to the subject matter of this manuscript. <u>Richard L. Schilsky</u>, Research support: ASCO receives research grants from the following companies to support the TAPUR trial: Astra-Zeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Genentech, Lilly, Merck, Pfizer, Seagen, Taiho. I do not personally receive any remuneration from these companies. I serve on the Board of Directors of the following companies: Clarified Precision Medicine, Leap Therapeutics, I serve as a consultant to the following companies: Bryologyx, Cellworks, Flatiron Health, Syapse, Zephyr AI I chair a DSMB for the following company: Toray Pharmaceuticals, <u>Bruce E. Johnson</u>, Post Marketing Royalties for EGFR mutation testing from DFCI, Paid Consultant to Novartis, Checkpoint Therapeutics, Astra Zeneca, Daichi Sankyo, GSK, Hummingbird Diagnostics, Genentech, Bluedot Bio, G1 Therapeutics, Jazz Pharmaceuticals, Merus, Abdera, and Simcere Pharmaceutical, Unpaid Member of Steering Committee for Pfizer, Research Support from Cannon Medical Imaging, <u>Andrew D. Cherniak</u>, Research support from Bayer, Paid Consultant to BirdsEye Bio, <u>Alanna J. Church</u>, Honoraria: The Jackson Laboratory Consulting or Advisory Role: AlphaSights, The Jackson Laboratory, Bayer Travel, Accommodations, Expenses: Bayer, <u>Katherine A. Janeway</u>, Honoraria: Foundation Medicine, Takeda, Consulting or Advisory Role: Bayer, Ipsen, Travel, Accommodations, Expenses: Bayer, The remaining authors declare no competing interests.
